Načítá se...
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
MGCD0103 is an isotype-selective inhibitor of histone deacetylases (HDACs) targeted to isoforms 1, 2, 3, and 11. In a phase 1 study in patients with leukemia or myelodysplastic syndromes (MDS), MGCD0103 was administered orally 3 times weekly without interruption. Twenty-nine patients with a median a...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society of Hematology
2008
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4081529/ https://ncbi.nlm.nih.gov/pubmed/18495956 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-10-115873 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|